Law360, New York (April 11, 2012, 2:07 PM EDT) -- A class of indirect purchasers of depression medication Wellbutrin XL and its generic equivalent on Monday beat a motion to nix class certification in their antitrust suit accusing GlaxoSmithKline PLC and Valeant Pharmaceuticals International of using sham patent litigation to delay generic competition.
U.S. District Judge Mary A. McLaughlin of the Eastern District of Pennsylvania ruled that the motion for reconsideration fell short of convincing her to reverse the class certification ruling.
“This is one of those decisions in which the court spent much time and...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.